1219739-36-2

Usage

Uses

Used in Pharmaceutical Industry:
5-((6-chloro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]-imidazol-2-yl)oxy)-2-methylbenzoic acid is used as a COX-2 inhibitor for its potential role in managing inflammation and pain. Its ability to block the production of pro-inflammatory substances makes it a candidate for the development of new anti-inflammatory drugs.
Used in Research Applications:
In the field of medical research, 5-((6-chloro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]-imidazol-2-yl)oxy)-2-methylbenzoic acid serves as a valuable compound for studying the mechanisms of inflammation and the effects of COX-2 inhibition. This research could lead to a better understanding of inflammatory diseases and the development of more effective treatments.
Used in Drug Development:
5-((6-chloro-5-(1-methyl-1H-indol-5-yl)-1H-benzo[d]-imidazol-2-yl)oxy)-2-methylbenzoic acid is used as a lead compound in the development of new pharmaceuticals targeting inflammatory conditions. Its unique structure and COX-2 inhibitory properties provide a foundation for the design of more potent and selective anti-inflammatory drugs.

Upstream product

• 335349-57-0 2-nitro-4-iodo-5-chloroaniline 
• 1219741-20-4 2, 4-chloro-5-iodobenzene-1,2-diamine 
• 1219741-21-5 3,5-chloro-6-iodo-1,3-dihydro-2H-benzimidazole-2-thione 
• 1219741-19-1 6-chloro-5-iodo-2-(methylsulfonyl)-1H-benzo[d]imidazole 
• 1219741-24-8 6-chloro-5-iodo-2-(methylsulfonyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazole 
• 1219741-39-5 methyl 5-[(6-chloro-5-iodo-1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-benzimidazol-2-yl)oxy]-2-methylbenzoate 
• 1219741-22-6 6-chloro-5-iodo-2-(methylthio)-1H-benzimidazole 
• 1635-61-6 5-chloro-2-nitroaniline 

Relevant academic research and scientific papers

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1′-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase

AMP-activated protein kinase (AMPK) plays an essential role as a cellular energy sensor and master regulator of metabolism in eukaryotes. Dysregulated lipid and carbohydrate metabolism resulting from insulin resistance leads to hyperglycemia, the hallmark of type 2 diabetes mellitus (T2DM). While pharmacological activation of AMPK is anticipated to improve these parameters, the discovery of selective, direct activators has proven challenging. We now describe a hit-to-lead effort resulting in the discovery of a potent and selective class of benzimidazole-based direct AMPK activators, exemplified by 5-((5-([1,1′-biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic acid, 42 (MK-3903). Compound 42 exhibited robust target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and insulin sensitization in mice.

NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.